BVF Inc. IL Sells 2,295,008 Shares of Septerna, Inc. $SEPN

BVF Inc. IL reduced its stake in shares of Septerna, Inc. (NASDAQ:SEPN) by 57.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,720,782 shares of the company’s stock after selling 2,295,008 shares during the period. Septerna makes up 1.6% of BVF Inc. IL’s investment portfolio, making the stock its 23rd biggest position. BVF Inc. IL’s holdings in Septerna were worth $47,975,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. Deutsche Bank AG lifted its holdings in shares of Septerna by 5.3% during the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after acquiring an additional 744 shares during the last quarter. Global Retirement Partners LLC bought a new stake in shares of Septerna during the 4th quarter worth $35,000. JPMorgan Chase & Co. lifted its holdings in shares of Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares during the last quarter. PharVision Advisers LLC lifted its holdings in shares of Septerna by 17.5% during the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after acquiring an additional 1,780 shares during the last quarter. Finally, Nuveen LLC lifted its holdings in shares of Septerna by 7.7% during the 4th quarter. Nuveen LLC now owns 25,798 shares of the company’s stock worth $719,000 after acquiring an additional 1,837 shares during the last quarter.

Analyst Upgrades and Downgrades

SEPN has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Truist Financial boosted their price target on shares of Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Raymond James Financial boosted their price target on shares of Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research note on Monday, June 8th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Septerna in a research note on Wednesday, May 13th. Finally, Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.78.

Septerna Trading Up 1.8%

Shares of NASDAQ:SEPN opened at $35.80 on Thursday. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -44.20 and a beta of 2.39. The company has a 50-day moving average price of $27.61 and a 200-day moving average price of $26.92. Septerna, Inc. has a 12 month low of $9.85 and a 12 month high of $37.01.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The firm had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, research analysts forecast that Septerna, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity

In other news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total transaction of $97,360.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $4,240,247.06. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Samira Shaikhly sold 11,798 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88. Following the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $23,837.58. This trade represents a 93.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 27,983 shares of company stock valued at $842,957. Insiders own 5.80% of the company’s stock.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.